Skip to main content

Table 1 Antiviral effects of title compounds against TMV in vivo at 500 μg/mL

From: Design, synthesis, antiviral bioactivities and interaction mechanisms of penta-1,4-diene-3-one oxime ether derivatives containing a quinazolin-4(3H)-one scaffold

Compound

R1

R2

R3

–O–

Curative activity(%)a

Protective activity(%)a

8a

H

Pyridin-2-yl

3-ClPh

4-O

44.6 ± 1.7

59.4 ± 1.6

8b

H

Pyridin-2-yl

3-MePh

4-O

40.1 ± 2.4

56.4 ± 1.3

8c

H

Pyridin-2-yl

2-ClPh

4-O

55.9 ± 2.9

69.8 ± 5.8

8d

H

Pyridin-2-yl

4-ClPh

4-O

53.4 ± 3.9

44.7 ± 3.2

8e

H

Pyridin-2-yl

2,4-di-ClPh

4-O

54.6 ± 4.5

60.1 ± 3.4

8f

Cl

Pyridin-2-yl

3-MePh

4-O

31.7 ± 3.8

39.4 ± 4.0

8g

Cl

Pyridin-2-yl

3-ClPh

4-O

33.4 ± 5.6

55.4 ± 4.9

8h

Cl

Pyridin-2-yl

2-ClPh

4-O

44.9 ± 4.7

52.1 ± 4.1

8i

Cl

Pyridin-2-yl

4-ClPh

4-O

45.3 ± 4.8

47.7 ± 6.3

8j

H

Pyridin-2-yl

2-ClPh

2-O

55.4 ± 4.3

67.7 ± 1.7

8k

H

Pyridin-2-yl

2,4-di-ClPh

2-O

59.1 ± 4.2

72.0 ± 3.9

8l

Cl

Pyridin-2-yl

2-ClPh

2-O

45.8 ± 6.1

48.9 ± 4.3

8m

Cl

Pyridin-2-yl

2,4-di-ClPh

2-O

50.5 ± 4.9

54.4 ± 3.9

8n

H

Thiophene-2-yl

2,4-di-ClPh

4-O

37.3 ± 6.1

50.3 ± 5.1

8o

H

Pyridin-3-yl

2-ClPh

4-O

53.5 ± 2.5

65.1 ± 6.2

8p

H

Pyridin-3-yl

3-MePh

4-O

37.4 ± 3.6

53.2 ± 3.5

Ningnanmycinb

–

–

–

–

51.8 ± 4.3

65.7 ± 2.9

  1. aAverage of three replicates
  2. bNingnanmycin was used as a comparision